Edwards Lifesciences (EW) Other Non-Current Liabilities (2009 - 2026)

Edwards Lifesciences has reported Other Non-Current Liabilities for 18 years, with the latest figure at $555.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 55.31% year-over-year to $555.4 million; the trailing twelve-month figure through Mar 2026 stood at $555.4 million (up 55.31% YoY), and the FY2025 full-year result was $502.7 million, up 34.66% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $555.4 million, up from $502.7 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $555.4 million in Q1 2026, with the low at $59.1 million in Q1 2022.
• Average Other Non-Current Liabilities over 5 years is $323.8 million, with a median of $316.1 million recorded in 2022.
• Year-over-year, Other Non-Current Liabilities sank 73.64% in 2022 and soared 340.1% in 2023.
• Tracing EW's Other Non-Current Liabilities over 5 years: stood at $267.5 million in 2022, then retreated by 10.17% to $240.3 million in 2023, then jumped by 55.35% to $373.3 million in 2024, then soared by 34.66% to $502.7 million in 2025, then increased by 10.48% to $555.4 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $555.4 million (Q1 2026), $502.7 million (Q4 2025), and $442.9 million (Q3 2025), per Business Quant data.

Peer Comparison